This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Antonadou, D. Articles by Throuvalas, N. Search for Related Content PubMed PubMed Citation Articles by Antonadou, D. Articles by Throuvalas, N. Social Bookmarking                            What's this?

Phase II Randomized Trial of Temozolomide and Concurrent Radiotherapy in Patients With Brain Metastases

From the Metaxas Cancer Hospital, Piraeus, Greece.

Address reprint requests to D. Antonadou, MD, Metaxas Cancer Hospital, 36 Kokinara St, 14562 Kifissia Greece, Piraeus, Greece; email: d_antona{at}hol.gr

PURPOSE: To determine the efficacy, tolerability, and safety of concurrent temozolomide and radiotherapy in patients with previously untreated brain metastases.

PATIENTS AND METHODS: Fifty-two patients with brain metastases from solid tumors were randomized to oral temozolomide (75 mg/m²/d) concurrent with 40-Gy fractionated conventional external-beam radiotherapy (2 Gy, 5 d/wk) for 4 weeks versus 40-Gy radiotherapy alone. The group receiving temozolomide and radiotherapy continued temozolomide therapy (200 mg/m²/d) for 5 days every 28 days for an additional six cycles. The primary end points were radiologic response and neurologic symptom evaluation.

RESULTS: The objective response rate was significantly (P = .017) improved in patients receiving temozolomide and radiotherapy versus radiotherapy alone. Among 24 patients assessable for response in the temozolomide group, 23 (96%) of 24 responded, including nine (38%) patients with a complete response and 14 (58%) patients with a partial response. With radiotherapy alone, 14 (67%) of 21 assessable patients responded, including seven (33%) complete responses and seven (33%) partial responses. There was marked neurologic improvement in the group receiving temozolomide, and the proportion of patients requiring corticosteroids 2 months after treatment was lower in the temozolomide group compared with radiotherapy alone (67% v 91%, respectively). Daily temozolomide concurrent with radiotherapy was generally well tolerated; however, grade 2 nausea (48% v 13%, P = .13) and vomiting (32% v 0%, P = .004) were significantly increased in the temozolomide group. Hematologic toxicity was predictable and reversible.

CONCLUSION: Temozolomide is safe, and a significant improvement in response rate was observed when administered in combination with radiotherapy in patients with previously untreated brain metastases. A larger randomized trial is warranted to verify these results.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				L. M. Krug and M. C. Pietanza Emerging Therapies in Small Cell Lung Cancer ASCO Educational Book, January 1, 2009; 2009(1): 455 - 460. [Abstract] [Full Text] [PDF]

				J. C. Buckner, P. D. Brown, B. P. O'Neill, F. B. Meyer, C. J. Wetmore, and J. H. Uhm Central Nervous System Tumors Mayo Clin. Proc., October 1, 2007; 82(10): 1271 - 1286. [Abstract] [Full Text] [PDF]

				A. F. Eichler and J. S. Loeffler Multidisciplinary Management of Brain Metastases Oncologist, July 1, 2007; 12(7): 884 - 898. [Abstract] [Full Text] [PDF]

				G. Y. Ku, G. Krol, and D. H. Ilson Successful Treatment of Leptomeningeal Disease in Colorectal Cancer With a Regimen of Bevacizumab, Temozolomide, and Irinotecan J. Clin. Oncol., May 1, 2007; 25(13): e14 - e16. [Full Text] [PDF]

				R. R. Patel and M. P. Mehta Targeted Therapy for Brain Metastases: Improving the Therapeutic Ratio Clin. Cancer Res., March 15, 2007; 13(6): 1675 - 1683. [Abstract] [Full Text] [PDF]

				D Schadendorf, A Hauschild, S Ugurel, A Thoelke, F Egberts, M Kreissig, R Linse, U Trefzer, T Vogt, W Tilgen, et al. Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study. Ann. Onc., October 1, 2006; 17(10): 1592 - 1597. [Abstract] [Full Text] [PDF]

				A. Cortot, L Geriniere, G Robinet, J-L Breton, R Corre, L Falchero, H Berard, C Gimenez, J-M Chavaillon, M Perol, et al. Phase II trial of temozolomide and cisplatin followed by whole brain radiotherapy in non-small-cell lung cancer patients with brain metastases: a GLOT-GFPC study Ann. Onc., September 1, 2006; 17(9): 1412 - 1417. [Abstract] [Full Text] [PDF]

				D. Khuntia, P. Brown, J. Li, and M. P. Mehta Whole-Brain Radiotherapy in the Management of Brain Metastasis J. Clin. Oncol., March 10, 2006; 24(8): 1295 - 1304. [Abstract] [Full Text] [PDF]

				K. F. Hofland, A. V. Thougaard, M. Dejligbjerg, L. H. Jensen, P. E.G. Kristjansen, P. Rengtved, M. Sehested, and P. B. Jensen Combining Etoposide and Dexrazoxane Synergizes with Radiotherapy and Improves Survival in Mice with Central Nervous System Tumors Clin. Cancer Res., September 15, 2005; 11(18): 6722 - 6729. [Abstract] [Full Text] [PDF]

				C. J. Langer and M. P. Mehta Current Management of Brain Metastases, With a Focus on Systemic Options J. Clin. Oncol., September 1, 2005; 23(25): 6207 - 6219. [Abstract] [Full Text] [PDF]

				N J Pease, A Edwards, and L J Moss Effectiveness of whole brain radiotherapy in the treatment of brain metastases: a systematic review Palliative Medicine, June 1, 2005; 19(4): 288 - 299. [Abstract] [PDF]

				N. U. Lin, J. R. Bellon, and E. P. Winer CNS Metastases in Breast Cancer J. Clin. Oncol., September 1, 2004; 22(17): 3608 - 3617. [Abstract] [Full Text] [PDF]

				S. S. Agarwala, J. M. Kirkwood, M. Gore, B. Dreno, N. Thatcher, B. Czarnetski, M. Atkins, A. Buzaid, D. Skarlos, and E. M. Rankin Temozolomide for the Treatment of Brain Metastases Associated With Metastatic Melanoma: A Phase II Study J. Clin. Oncol., June 1, 2004; 22(11): 2101 - 2107. [Abstract] [Full Text] [PDF]

				L. Tentori, C. Leonetti, M. Scarsella, G. d'Amati, M. Vergati, I. Portarena, W. Xu, V. Kalish, G. Zupi, J. Zhang, et al. Systemic Administration of GPI 15427, a Novel Poly(ADP-Ribose) Polymerase-1 Inhibitor, Increases the Antitumor Activity of Temozolomide against Intracranial Melanoma, Glioma, Lymphoma Clin. Cancer Res., November 1, 2003; 9(14): 5370 - 5379. [Abstract] [Full Text] [PDF]

				E. L. Chang and S. Lo Diagnosis and Management of Central Nervous System Metastases from Breast Cancer Oncologist, October 1, 2003; 8(5): 398 - 410. [Abstract] [Full Text] [PDF]